DSV A/S
DSV, 1153 - DSV OBTAINS ALL REGULATORY CLEARANCES FOR THE ACQUISITION OF SCHENKER
DSV, 1153 - DSV OBTAINS ALL REGULATORY CLEARANCES FOR THE ACQUISITION OF SCHENKER
Company Announcement No. 1153
As of today, all closing conditions for DSV A/S’ pending acquisition of the global freight forwarding and contract logistics business DB Schenker operated by Schenker AG and its affiliates (“Schenker”) from Deutsche Bahn AG have been fulfilled, including approval by the European Commission and the expiration of the applicable waiting period in the US. Please refer to announcement no. 1132 of 13 September 2024.
The parties are now able to complete the transaction, which is expected to take place on 30 April 2025.
Due to the expected completion of the Schenker acquisition, the interim results for the first quarter of 2025 for DSV A/S, which is scheduled for 29 April 2025, will be postponed to 30 April 2025, where further details and preliminary financial information related to the acquisition of Schenker will be announced.
Contacts DSV:
Investor Relations
Stig Frederiksen, tel. +45 43 20 36 38, stig.frederiksen@dsv.com
Alexander Plenborg, tel. +45 43 20 33 73, alexander.plenborg@dsv.com
Media
Jonatan Rying Larsen, tel. +45 25 41 77 37, press@dsv.com
Yours sincerely,
DSV A/S
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
CGTN31.8.2025 12:50:06 CEST | Press release
CGTN: President Xi highlights friendship, cooperation and multilateralism at SCO Summit
Novo Nordisk A/S31.8.2025 09:09:18 CEST | Press release
Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas
Novartis Pharma AG30.8.2025 17:00:00 CEST | Press release
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
F. Hoffmann-La Roche Ltd30.8.2025 16:30:00 CEST | Press release
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
CGTN30.8.2025 11:44:44 CEST | Pressemeddelelse
CGTN: Arven efter Flying Tigers fejres for at styrke det varige bånd mellem Kina og USA
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom